{"url_path":"/sec/phge/8-k/2026-06-05/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1739174/0001213900-26-065850-index.html","accession_number":"0001213900-26-065850","cik":"0001739174","ticker":"PHGE","issuer_name":"BiomX Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1739174/0001213900-26-065850-index.html","primary_entity_key":"0001739174","primary_entity_name":"BiomX Inc."},"word_count":107,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n4.1\n \n[Form of 12% Convertible Promissory Note](ea029375001ex4-1.htm)\n\n4.2\n \n[Warrant to Purchase Common Stock, dated May 13, 2026](ea029375001ex4-2.htm)\n\n10.1\n \n[Line of Credit Agreement, dated as of May 13, 2026, between BiomX Inc. and Mandragola Ltd.](ea029375001ex10-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n2\n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nBIOMX INC.\n \n\n \n \n\nDate: June 5, 2026\n \n\n \n \n\nBy:\n/s/ Michael Oster\n \n\nName: \nMichael Oster\n \n\nTitle:\nChief Executive Officer\n \n\n \n \n\n3"}